tk-112690
Small moleculeexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started May 15, 2019 (NCT04046250)
Timeline
2010s
- Jan 1, 2019
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Uridine phosphorylase 1INHIBITOR
UPP1 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
Cc1cn2c(nc1=O)O[C@H]1[C@H](O)[C@@H](CO)O[C@H]12- Mol. weight
- 240.22 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3251296 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05658016 | Phase 2 | Jun 17, 2022 | Tosk, Inc. |
| NCT05669521 | Phase 2 | Jun 15, 2022 | Tosk, Inc. |
| NCT04046250 | Phase 2 | May 15, 2019 | Crystal Life Sciences, Tosk, Inc. |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Tosk, Inc. | For profit | 3 | 3 | 1 | 2019 |
| Crystal Life Sciences | For profit | 1 | 0 | 1 | 2019 |
2 organizations
Page 1 / 1